The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance wi
The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.
대표청구항▼
1. A method of reducing intraocular pressure, the method comprising administering to a human or other animal a safe and effective amount of a compound derived from the esterification of a carboxylate functionality of a drug moiety with a sugar alcohol selected from the group consisting of threitol,
1. A method of reducing intraocular pressure, the method comprising administering to a human or other animal a safe and effective amount of a compound derived from the esterification of a carboxylate functionality of a drug moiety with a sugar alcohol selected from the group consisting of threitol, erythritol, arabinitol, xylitol, ribitol, lyxitol, glucitol, galactitol, mannitol, gulitol, altitol, allitol, iditol, talitol, 2-deoxyribitol, 2-deoxyglucitol, 2-deoxyxylitol, and a mixture thereof, the drug moiety comprising at least one of a phenoxyacetic acid, a cinnamic acid, and a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein the phenoxyacetic acid is selected from the group consisting of ticrynafen, ethacrynic acid, and a mixture thereof. 3. The method of claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid, gel, cream, and ointment. 4. The method of claim 1, wherein the carrier comprises a physiological saline solution. 5. The method of claim 4, wherein the saline solution is maintained at a pH between 4.5 and 8.0. 6. The method of claim 1, wherein the composition further comprises at least one of a pharmaceutically-acceptable preservative, stabilizer and surfactant. 7. The method of claim 1, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ticrynafen. 8. The method of claim 1, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ethacrynic acid. 9. The method of claim 1, wherein the drug moiety comprises cinnamic acid. 10. A method of reducing intraocular pressure, the method comprising administering to a human or other animal a safe and effective amount of a compound derived from the esterification of a carboxylate functionality of a drug moiety with a sugar alcohol selected from the group consisting of threitol, erythritol, arabinitol, xylitol, ribitol, lyxitol, glucitol, galactitol, mannitol, gulitol, altitol, allitol, iditol, talitol, and a mixture thereof, the drug moiety comprising at least one of a phenoxyacetic acid, a cinnamic acid, and a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 11. The method of claim 10, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is selected from the group consisting of ticrynafen, ethacrynic acid, and a mixture thereof. 12. The method of claim 10, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ticrynafen. 13. The method of claim 10, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ethacrynic acid. 14. The method of claim 10, wherein the drug moiety comprises cinnamic acid. 15. The method of claim 10, wherein the composition further comprises at least one of a pharmaceutically-acceptable preservative, stabilizer and surfactant. 16. The method of claim 10, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid, gel, cream, and ointment. 17. The method of claim 10, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a saline solution, gel, cream, and ointment. 18. A method of reducing intraocular pressure, the method comprising administering to a human or other animal a safe and effective amount of a compound derived from the esterification of a carboxylate functionality of a drug moiety with a sugar alcohol selected from the group consisting of threitol, erythritol, arabinitol, xylitol, ribitol, lyxitol, glucitol, galactitol, gulitol, altitol, allitol, iditol, talitol, 2-deoxyribitol, 2-deoxyglucitol, 2-deoxyxylitol, and a mixture thereof, the drug moiety comprising at least one of a phenoxyacetic acid, a cinnamic acid, and a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 19. The method of claim 18, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is selected from the group consisting of ticrynafen, ethacrynic acid, and a mixture thereof. 20. The method of claim 18, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ticrynafen. 21. The method of claim 18, wherein the drug moiety comprises a phenoxyacetic acid and the phenoxyacetic acid is ethacrynic acid. 22. The method of claim 18, wherein the drug moiety comprises cinnamic acid. 23. The method of claim 18, wherein the composition further comprises at least one of a pharmaceutically-acceptable preservative, stabilizer and surfactant. 24. The method of claim 18, wherein the pharmaceutically acceptable carrier comprises an ophthalmically acceptable pharmaceutical excipient. 25. The method of claim 18, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid, gel, cream, and ointment.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
Burk,Robert M.; Holoboski,Mark; Posner,Mari F., ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists.
Wos John August ; deLong Mitchell Anthony ; Amburgey ; Jr. Jack S. ; Dai Haiyan George ; Miley Cynthia Jean ; De Biswanath, Aromatic C.sub.16 -C.sub.20 -substituted tetrahydro prostaglandins useful as FP agonists.
Wos John August ; deLong Mitchell Anthony ; Amburgey ; Jr. Jack S. ; De Biswanath ; Dai Haiyan George ; Wang Yili, Aromatic C.sub.16 -C.sub.20 -substituted tetrahydro prostaglandins useful as FP agonists.
Wos John August ; deLong Mitchell Anthony ; Amburgey ; Jr. Jack S. ; Dai Haiyan George ; De Biswanath ; Soper David Lindsey, Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists.
Mitchell Anthony deLong ; Jack Snyder Amburgey, Jr. ; John August Wos ; Biswanath De ; David Lindsey Soper, C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists.
Mitchell Anthony deLong ; Jack Snyder Amburgey, Jr. ; John August Wos ; Biswanath De ; David Lindsey Soper, C11 oxymyl and hydroxylamino prostaglandins useful as medicaments.
Bartmann Wilhelm (Bad Soden am Taunus DEX) Beck Gerhard (Frankfurt am Main DEX) Lerch Ulrich (Hofheim am Taunus DEX) Scholkens Bernward (Kelkheim DEX), Esters of 5-methyl-10,11-dihydroprostaglandin-A1.
Ashton Paul ; Crooks Peter Anthony ; Cynkowski Tadeusz ; Cynkowska Grazyna ; Guo Hone, Means to achieve sustained release of synergistic drugs by conjugation.
Godlewski Michael Selden ; Klopfenstein Sean Rees ; Mundla Sreenivasa Reddy ; Seibel William Lee ; Muth Randy Stuart, Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives.
Roberts, Jeannette C.; Wilmore, Britta H.; Cassidy, Pamela B.; Dominick, Pamela K.; Short, Megan D., Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.